You are here: Home > Prescription(RX) Drugs > P > Prascionra (Prasco Laboratories)

Name:Prascionra
Manufacturer:Prasco Laboratories
Category:Prescription Marketed Drugs


Prascion® RA Cream With Sunscreens sodium sulfacetamide 10% and sulfur 5%

PRASCION RA - sulfacetamide sodium and sulfur cream 
Prasco Laboratories

Disclaimer: This drug has not been found by FDA to be safe and effective, and this labeling has not been approved by FDA. For further information about unapproved drugs, click here.

----------

Prascion® RA Cream With Sunscreens sodium sulfacetamide 10% and sulfur 5%

Rx only
DESCRIPTION: Each gram of Prascion® RA Cream With Sunscreens contains 100 mg of sodium sulfacetamide and 50 mg of sulfur in a cream containing avobenzone, benzyl alcohol NF, cetyl alcohol NF, cocoglycerides, dimethicone 200/100, edetate disodium USP, fragrance, glyceryl stearate/Peg-100 stearate, isopropyl myristate NF, light mineral oil NF, octinoxate USP, polysorbate 60 NF, propylene glycol USP, purified water USP, sodium thiosulfate USP, sorbitan monostearate NF, stearyl alcohol NF, xanthan gum NF.

Sodium sulfacetamide is a sulfonamide with antibacterial activity while sulfur acts as a keratolytic agent. Chemically, sodium sulfacetamide is N-[(4-aminophenyl) sulfonyl]-acetamide, monosodium salt, monohydrate. The structural formula is:

structure

CLINICAL PHARMACOLOGY: The most widely accepted mechanism of action of sulfonamides is the Woods-Fildes theory, which is based on the fact that sulfonamides act as competitive antagonists to para-aminobenzoic acid (PABA), an essential component for bacterial growth. While absorption through intact skin has not been determined, sodium sulfacetamide is readily absorbed from the gastrointestinal tract when taken orally and excreted in the urine, largely unchanged. The biological half-life has variously been reported as 7 to 12.8 hours.

The exact mode of action of sulfur in the treatment of acne is unknown, but it has been reported that it inhibits the growth of Propionibacterium acnes and the formation of free fatty acids.

INDICATIONS AND USAGE: Prascion RA Cream With Sunscreens is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis.

CONTRAINDICATIONS: Prascion RA Cream With Sunscreens is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. This drug is not to be used by patients with kidney disease.

WARNINGS: Although rare, sensitivity to sodium sulfacetamide may occur. Therefore, caution and careful supervision should be observed when prescribing this drug for patients who may be prone to hypersensitivity to topical sulfacetamides. Systemic toxic reactions such as agranulocytosis, acute hemolytic anemia, purpura hemorrhagica, drug fever, jaundice, and contact dermatitis indicated hypersensitivity to sulfonamides. Particular caution should be employed if areas of denuded or abraded skin are involved.

PRECAUTIONS: General - If irritation develops, use of the product should be discontinued and appropriate therapy instituted. For external use only. Keep away from eyes. Patients should be carefully observed for possible local irritation or sensitization during long-term therapy. The object of this
therapy is to achieve desquamation without irritation, but sodium sulfacetamide and sulfur can cause reddening and scaling of epidermis. These side effects are not unusual in the treatment of acne vulgaris, but patients should be cautioned about the possibility.
Keep out of reach of children.

Carcinogenesis, Mutagenesis and Impairment of Fertility - Long-term studies in animals have not been performed to evaluate carcinogenic potential.

Pregnancy - Category C. Animal reproduction studies have not been conducted with Prascion® RA Cream With Sunscreens. It is also not known whether this drug can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. It should be given to a pregnant woman only if clearly needed.

Nursing Mothers - It is not known whether sodium sulfacetamide is excreted in human milk following topical use of Prascion® RA Cream With Sunscreens. However, small amounts of orally administered sulfonamides have been reported to be eliminated in human milk. In view of this and because many drugs are excreted in human milk, caution should be exercised when this drug is administered to a nursing woman.

Pediatric Use - Safety and effectiveness in children under the age of 12 have not been established.

ADVERSE REACTIONS: Although rare, sodium sulfacetamide may cause local irritation.

DOSAGE AND ADMINISTRATION: Apply a thin film of Prascion RA Cream With Sunscreens to affected areas 1 to 3 times daily.

HOW SUPPLIED: NDC 66993-904-45 in 45 g tubes.

Store at controlled room temperature 15°-30°C (59°-86°F).

Manufactured for: Prasco Laboratories
                           Mason, OH 45040 USA
Manufactured by: Groupe Parima, Inc.
                           Montreal, QC H4S 1X6 CANADA

cartontube


PRASCION  RA
sodium sulfacetamide and sulfur cream
Product Information
Product Type HUMAN PRESCRIPTION DRUG Item Code (Source) NDC:66993-904
Route of Administration TOPICAL DEA Schedule     
Active Ingredient/Active Moiety
Ingredient Name Basis of Strength Strength
SULFACETAMIDE SODIUM (SULFACETAMIDE) SULFACETAMIDE SODIUM 100 mg  in 1 g
SULFUR (SULFUR) SULFUR 50 mg  in 1 g
Inactive Ingredients
Ingredient Name Strength
AVOBENZONE  
BENZYL ALCOHOL  
CETYL ALCOHOL  
COCO-GLYCERIDES  
DIMETHICONE  
EDETATE DISODIUM  
GLYCERYL MONOSTEARATE  
POLYOXYL 100 STEARATE  
ISOPROPYL MYRISTATE  
LIGHT MINERAL OIL  
OCTINOXATE  
POLYSORBATE 60  
PROPYLENE GLYCOL  
WATER  
SODIUM THIOSULFATE  
SORBITAN MONOSTEARATE  
STEARYL ALCOHOL  
XANTHAN GUM  
Product Characteristics
Color      Score     
Shape Size
Flavor Imprint Code
Contains     
Packaging
# Item Code Package Description Multilevel Packaging
1 NDC:66993-904-45 1 TUBE ( TUBE) in 1 CARTON contains a TUBE
1 45 g in 1 TUBE This package is contained within the CARTON (66993-904-45)

Marketing Information
Marketing Category Application Number or Monograph Citation Marketing Start Date Marketing End Date
unapproved drug other 12/22/2010

Labeler - Prasco Laboratories (065969375)
Registrant - Groupe PARIMA, Inc. (252437850)
Establishment
Name Address ID/FEI Operations
Groupe PARIMA, Inc. 252437850 manufacture

Revised: 12/2010 Prasco Laboratories



Source: http://dailymed.nlm.nih.gov
Reproduced with permission of U.S. National Library of Medicine


Copyright © 2020 Drugsdb.eu by Dionisios Fentas || Terms of Use

Loading

Prescription Marketed Drugs Alphabetically
A| B| C| D| E| F| G| H| I| J| K| L| M| N| O| P| Q| R| S| T| U| V| W| X| Y| Z| 0-9

Categories:
Prescription(RX) Drugs
Over-the-counter (OTC) Drugs
Homeopathic Drugs
Animal Drugs
Feedback